Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-fat diet promotes colorectal cancer via carnitine/acetylcarnitine-driven CPT1A metabolic reprogramming and the intervention of β-hydroxybutyrate.

Oncogene·2026
Same author

QTLNetwork-MP: integrative mapping of additive, epistatic, and G × E effects for complex traits in multiparent advanced generation intercross populations.

Briefings in bioinformatics·2026
Same author

Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15<sup>+</sup> Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

TAF1 aggravates ferroptosis by promoting the ubiquitin-mediated degradation of nuclear GPX4.

Journal of Zhejiang University. Science. B·2026
Same author

SPTEdU-seq enables parallel optics-free newborn cell tracking and spatial total transcriptional dynamics in intact microenvironments.

Cell stem cell·2026
Same author

Exploring autism spectrum profiles via network analysis of parent-reported ASSQ patterns.

BMC psychiatry·2026
Same journal

Correction: Reis et al. Bioinks Enriched with ECM Components Obtained by Supercritical Extraction. <i>Biomolecules</i> 2022, <i>12</i>, 394.

Biomolecules·2026
Same journal

Correction: Kim, K.-H.; Yoo, B.C. Gintonin as a Lysophosphatidic Acid-Enriched GPCR Ligand System: Molecular Architecture and Receptor Pharmacology in <i>Panax ginseng</i>. <i>Biomolecules</i> 2026, <i>16</i>, 465.

Biomolecules·2026
Same journal

Correction: Bastyte et al. The Association of Vitamin D Receptor Gene Polymorphisms with Vitamin D, Total IgE, and Blood Eosinophils in Patients with Atopy. <i>Biomolecules</i> 2024, <i>14</i>, 212.

Biomolecules·2026
Same journal

AtHSPR Plays a Positive Role in Arabidopsis Resistance Against <i>Pseudomonas syringae</i> pv. <i>tomato</i> DC3000 by Interacting with TOP1.

Biomolecules·2026
Same journal

CYTH4 Facilitates Renal Cell Carcinoma via Enhancing Proliferation and Likely Immune Evasion.

Biomolecules·2026
Same journal

Integrated Immune-Gut Profiling Identifies an Exploratory Pediatric Inflammatory Intestinal Profile Associated with Food-Specific IgG Reactivity.

Biomolecules·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

DB-2B, a Novel and Selective STAT3 Inhibitor Inhibits Colorectal Cancer Progression In Vitro and In Vivo.

Yuting Chen1,2,3, Dianyang Li4, Mengdi Zhang5

  • 1Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.

Biomolecules
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

A new drug, DB-2B, effectively inhibits signal transducer and activator of transcription 3 (STAT3) in colorectal cancer (CRC) cells. This STAT3 inhibitor shows promise for targeted CRC treatment by suppressing tumor growth and improving survival.

Keywords:
DB-2BSH2 domainSTAT3 inhibitoranticancercolorectal canceroral administrationsmall molecule inhibitorstemness

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Related Experiment Videos

Last Updated: May 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) activation is linked to tumor progression and poor prognosis in colorectal cancer (CRC).
  • Limited availability of clinical STAT3 inhibitors impedes personalized CRC treatment strategies.
  • Targeting STAT3 is crucial for developing novel therapies for CRC.

Purpose of the Study:

  • To develop and evaluate a novel small-molecule STAT3 inhibitor, DB-2B, for targeting colorectal cancer (CRC) progression.
  • To investigate the efficacy of DB-2B in inhibiting STAT3 activation and its downstream pathways in CRC.
  • To assess the therapeutic potential of DB-2B in preclinical models of CRC.

Main Methods:

  • In silico molecular docking was employed to predict the binding of DB-2B to STAT3.
  • Biophysical techniques including surface plasmon resonance and isothermal titration calorimetry validated STAT3-DB-2B interaction.
  • In vitro assays (Western blotting, immunofluorescence, cell proliferation, apoptosis, cell cycle, stemness assays) and in vivo studies in CRC models were conducted.

Main Results:

  • DB-2B demonstrated specific binding to STAT3, inhibiting its activation and nuclear translocation.
  • In vitro, DB-2B suppressed CRC cell proliferation, induced apoptosis, arrested cell cycle, and reduced stemness.
  • In vivo, DB-2B exhibited good oral bioavailability and safety, significantly inhibiting CRC progression.

Conclusions:

  • DB-2B is a potent small-molecule inhibitor of STAT3 with significant anti-CRC activity.
  • DB-2B effectively targets STAT3 signaling pathways, offering a potential therapeutic strategy for colorectal cancer.
  • This study highlights DB-2B as a promising candidate for the targeted treatment of CRC.